ABT · ABBOTT LABORATORIES

Back to holdings

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Close · 3M

+16.95%

Held by 1 AI ETF

AIVL0.248%

as of Oct 23

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals17

Win rate18% (3/17)

Avg buy return-4.96%

AIVLnow 0.248% of fund25 signals

AIVL · Weight increase · 2d

weight 0.240% → 0.248% (+0.008 pp)·stock up 2.6% in the 30 days before

Oct 23·entry $103.70·now $103.70Fresh

0.00%

since Oct 23

AIVL · Weight decrease · 3d

weight 0.253% → 0.240% (-0.013 pp)·stock down 3.1% in the 30 days before

Oct 21·entry $100.51·now $103.70

+3.17%

since Oct 21

AIVL · Weight decrease · 2d

weight 0.253% → 0.245% (-0.008 pp)·stock down 0.5% in the 30 days before

Oct 20·entry $102.45·now $103.70

+1.22%

since Oct 20

AIVL · Accumulation · 5d

weight 0.241% → 0.253% (+0.011 pp)·stock up 2.3% in the 30 days before

Oct 15·entry $104.68·now $103.70Fresh

-0.94%

since Oct 15

AIVL · Weight increase · 3d

weight 0.242% → 0.251% (+0.008 pp)·stock up 0.9% in the 30 days before

Oct 14·entry $102.97·now $103.70Fresh

+0.71%

since Oct 14

AIVL · Weight increase · 2d

weight 0.242% → 0.249% (+0.006 pp)·stock down 0.5% in the 30 days before

Oct 13·entry $102.61·now $103.70Fresh

+1.06%

since Oct 13

AIVL · Weight decrease · 3d

weight 0.817% → 0.239% (-0.578 pp)·stock down 11.7% in the 30 days before

Oct 2·entry $97.50·now $103.70

+6.36%

since Oct 2

AIVL · Weight decrease · 2d

weight 0.817% → 0.785% (-0.033 pp)·stock down 11.2% in the 30 days before

Oct 1·entry $96.69·now $103.70

+7.25%

since Oct 1

AIVL · Weight increase · 2d

weight 0.813% → 0.817% (+0.004 pp)·stock down 9.5% in the 30 days before

Sep 28·entry $100.98·now $103.70Drifting

+2.69%

since Sep 28

AIVL · Weight decrease · 2d

weight 0.832% → 0.806% (-0.026 pp)·stock down 8.1% in the 30 days before

Sep 11·entry $101.95·now $103.70

+1.72%

since Sep 11

AIVL · Weight decrease · 3d

weight 0.945% → 0.842% (-0.102 pp)·stock up 2.9% in the 30 days before

Sep 3·entry $108.79·now $103.70

-4.68%

since Sep 3

AIVL · Weight decrease · 2d

weight 0.945% → 0.863% (-0.082 pp)·stock up 4.8% in the 30 days before

Sep 2·entry $110.47·now $103.70

-6.13%

since Sep 2

AIVL · Weight decrease · 3d

weight 0.982% → 0.939% (-0.044 pp)·stock up 3.3% in the 30 days before

Aug 27·entry $111.59·now $103.70

-7.07%

since Aug 27

AIVL · Weight decrease · 2d

weight 0.982% → 0.955% (-0.028 pp)·stock up 6.4% in the 30 days before

Aug 26·entry $114.10·now $103.70

-9.11%

since Aug 26

AIVL · Accumulation · 5d

weight 0.923% → 0.978% (+0.055 pp)·stock up 11.1% in the 30 days before

Aug 25·entry $116.13·now $103.70Fresh

-10.70%

since Aug 25

AIVL · Accumulation · 5d

weight 0.926% → 0.983% (+0.057 pp)·stock up 13.2% in the 30 days before

Aug 24·entry $116.67·now $103.70Fresh

-11.12%

since Aug 24

AIVL · Accumulation · 5d

weight 0.930% → 0.983% (+0.053 pp)·stock up 15.8% in the 30 days before

Aug 21·entry $116.64·now $103.70Fresh

-11.09%

since Aug 21

AIVL · Accumulation · 5d

weight 0.922% → 0.963% (+0.040 pp)·stock up 13.5% in the 30 days before

Aug 20·entry $114.14·now $103.70Fresh

-9.15%

since Aug 20

AIVL · Accumulation · 5d

stock up 14.8% in the 30 days before

Aug 19·entry $114.43·now $103.70Fresh

-9.38%

since Aug 19

AIVL · Accumulation · 5d

stock up 10.8% in the 30 days before

Aug 18·entry $112.68·now $103.70Fresh

-7.97%

since Aug 18

AIVL · Weight decrease · 2d

stock up 12.6% in the 30 days before

Aug 14·entry $111.25·now $103.70

-6.79%

since Aug 14

AIVL · Accumulation · 5d

stock up 24.6% in the 30 days before

Aug 13·entry $111.27·now $103.70Fresh

-6.80%

since Aug 13

AIVL · Weight increase · 3d

stock up 24.7% in the 30 days before

Aug 12·entry $110.91·now $103.70Fresh

-6.50%

since Aug 12

AIVL · Weight increase · 2d

stock up 19.1% in the 30 days before

Aug 11·entry $109.72·now $103.70Fresh

-5.49%

since Aug 11

AIVL · Weight increase · 2d

stock up 13.4% in the 30 days before

Aug 6·entry $107.96·now $103.70Fresh

-3.95%

since Aug 6

LQAIno longer held2 signals

LQAI · Exit · 1d

weight 0.180% → 0 (exited)·stock down 10.2% in the 30 days before

Sep 29·entry $100.95·now $103.70

+2.72%

since Sep 29

LQAI · New entry · 1d

stock up 13.4% in the 30 days before

Aug 6·entry $107.96·now $103.70Fresh

-3.95%

since Aug 6

AIEQno longer held2 signals

AIEQ · Exit · 1d

stock up 14.7% in the 30 days before

Aug 2·entry $107.12·now $103.70

-3.19%

since Aug 2

AIEQ · Weight increase · 2d

stock up 16.4% in the 30 days before

Jul 30·entry $105.61·now $103.70Fresh

-1.81%

since Jul 30

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.

Buffett-style framework

Fails the frameworkas of Oct 25

AIVL holds a small 0.248% position and has been nudging it up and down in tiny steps, with a mild net accumulation trend in mid-to-late October. That is a modest, maintenance-style stance that disagrees with the Fail verdict only mildly, since the position is too small to be a real conviction bet against the valuation and returns concerns.

Circle of CompetenceAbbott's mix of diagnostics, medical devices, nutrition and established pharmaceuticals has steady, recurring demand and predictable unit economics, so ten-year cash flows can be reasonably projected.
Economic MoatSwitching costs, regulatory approvals, clinician familiarity and global scale in products like continuous glucose monitors, cardiovascular devices and infant formula form a durable moat.
ManagementFinancials alone cannot show candor or insider ownership, though a record of steady dividend growth and the disciplined spinoff of AbbVie point to sound capital allocation.
Financial HealthA reported ROE of 10.52% falls well short of the 15% ten-year average the framework requires, even though revenue growth of 10% and a manageable balance sheet are positives.
Margin of SafetyA P/E of 37.9 and EV/EBITDA of 26.3 price in years of flawless execution, leaving no margin of safety against a conservative estimate of owner earnings.

Abbott sits comfortably inside the circle of competence and has a real moat, but its ROE is below the framework's bar and the price of nearly 38 times earnings offers no margin of safety. It is a good business that this framework would want to revisit at a much lower price.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.